2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Computational Biology, Treatment Considerations, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3135 The PU.1/Spi1 transcription factor plays a crucial role in regulating gene expression in DNMT3AR882H/C clonal haematopoiesis

Jessica Beatrice Taube, MBChB, Tanya Rapoz D'Silva2, Lingyi Wang, PhD3, Marc R. Mansour, MD, PhD, FRCPath, MRCP4
1 University College London Cancer Institute, London, United Kingdom
2 University College London Cancer Institute, London, United Kingdom
3 University College London Cancer Institute, London, United Kingdom
4 University College London Cancer Institute, London, United Kingdom

DNMT3AR882H/C is commonly mutated in clonal haematopoiesis of indeterminate potential (CHIP) and increases the risk of developing myeloid malignancy. The molecular mechanism of increased clonal fitness for DNMT3AR882H/C haematopoietic stem and progenitor cells (HSPCs) is incompletely understood: while biochemical analysis suggests that DNMT3AR882H/C binds less strongly to DNA and has impaired methylation capacity, global methylation is only slightly reduced in mutant cells. Differentially methylated regions (DMR), however, can be more hypomethylated with DNMT3AR882H/C, compared to other DNMT3A mutations found in CHIP, which has led to the hypothesis that it has a dominant negative effect. Despite extensive study, the endogenous molecular mechanism to explain how this would result in increased clonal fitness or malignant risk remains unclear.

We hypothesised that focal hypomethylation in mutant HSPCs is caused by site-specific binding of wild-type (WT) or R882H/C DNMT3A with localised reduced methylation capacity. Reduced methylation at cis-regulatory elements (CRE) could increase chromatin accessibility, modify gene-regulation by transcription factors (TF) or chromatin remodellers and thus alter the transcriptional programme of CHIP cells to promote survival or malignant transformation.

To explore this question, we have developed murine cell line models of Dnmt3a+/R878C CHIP (the murine equivalent of R882C) in 416B HSCPs using CRISPR/Cas9-homology directed repair (HDR) (hereafter called KI cells) with isogenic WT controls. We first performed whole genome bisulphite sequencing and uncovered significant focal hypomethylation at DMR (3512 hypomethylated of total 5333) in KI cells, specifically at enhancer-like sequences (ELS). Motif analysis of these enhancer DMR revealed significant enrichment of the PU.1/Spi1 motif, a known master regulator of haematopoiesis.

ATAC-Seq demonstrated an overall increase in chromatin accessibility in KI cells (1838 gained differentially accessible regions (DAR), fdr 0.05, log2fc>1). KI-gained DAR were also enriched for ELS. Footprint analysis of ATAC-Seq data was used to infer TF binding to accessible regions. Strikingly, this revealed that Spi1 was the most significant differentially bound TF in the KI cells. Spi1 footprints were also enriched in overlapping regions of KI-hypomethylated DMRs and KI-gained DARs (OR 7.02, fdr 1.85e-34). We performed RNA-Seq on WT and KI cell lines, including differential expression analysis. Spi1 target genes had significantly increased expression in KI cells, including genes involved in myeloid differentiation and inflammatory response.

Further work in the lab will unpick Spi1’s site-specific functions in Dnmt3aR878C and if there are interacting factors (TF or chromatin remodellers) that cooperate with Spi1. Spi1 is involved in directing myeloid and lymphoid differentiation, in responding to inflammatory signals, as well as in regulating stem-like phenotypes and it is therefore a plausible factor to mediate the clonal advantage of DNMT3AR882H/C HSPCs. These results suggest a novel mechanism for DNMT3AR882H/C mutations to exert their impact on HSPCs: impaired focal methylation at ELS leads to increased accessibility of Spi1 binding sites in mutant cells, causing an altered HSPC transcriptome and promoting clonal survival in the aging bone marrow niche or under inflammatory stress.

Finally we have also used CRISPR/Cas9-HDR and prime editing to generate single-allele epitope-tagged Dnmt3a cell lines, tagging either the WT or R878C allele in different clones. These clones provide a powerful model with which to interrogate the underlying epigenetic mechanisms of DNMT3AR882H/C. They will be used to determine genome-wide localisation of each Dnmt3a variant, which will be correlated with methylation patterns and with the proposed Spi1-mediated gene-regulatory mechanism.  Further understanding of these molecular mechanisms could ultimately lead to the discovery of therapeutic targets with which to prevent malignant progression.

Jessica Beatrice Taube, MBChB: No relevant conflicts of interest to declare.